The Value of miR-296 and miR-517c in Evaluating the Prognosis of Patients with Glioma after Radiotherapy and Chemotherapy

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="8"><hr/></td></tr><tr class="thead"><td class="align_left">Total efficiency</td><td class="align_center">Complete remission rate</td><td class="align_center">Partial remission rate</td><td class="align_center">Stable rate</td><td class="align_center">Progress rate</td><td class="align_center">Overall survival rate</td><td class="align_center">Progression-free survival rate</td><td class="align_center">Progressive survival rate</td></tr><tr><td class="thead-hr" colspan="8"><hr/></td></tr><tr><td class="align_left">269/732 (36.75%)</td><td class="align_center">137/732 (18.72%)</td><td class="align_center">141/732 (19.26%)</td><td class="align_center">280/732 (38.25%)</td><td class="align_center">128/732 (17.49%)</td><td class="align_center">284/732 (38.79%)</td><td class="align_center">187/732 (25.54%)</td><td class="align_center">47/732 (6.42%)</td></tr><tr class="table-tr"><td colspan="8"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Curative effect and follow-up.</div>

Journal of Oncology

tab3

Table 3

Table 3: The Value of miR-296 and miR-517c in Evaluating the Prognosis of Patients with Glioma after Radiotherapy and Chemotherapy 